[
    {
     "kind": "calendar#event",
     "etag": "\"3356568056402000\"",
     "id": "boa5cbh7as7ai4bdu96hu5acs0",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=Ym9hNWNiaDdhczdhaTRiZHU5Nmh1NWFjczAgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2023-03-08T14:00:28.000Z",
     "updated": "2023-03-08T14:00:28.201Z",
     "summary": "IONS Ionis Pharmaceuticals, Inc. PDUFA",
     "description": "2023-12-22 The application has been given a Prescription Drug User Fee Act (PDUFA) action date of Dec. 22, 2023. https://www.prnewswire.com/news-releases/ionis-announces-fda-acceptance-of-new-drug-application-for-eplontersen-for-the-treatment-of-hereditary-transthyretin-mediated-amyloid-polyneuropathy-attrv-pn-301764027.html",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2023-12-22"
     },
     "end": {
      "date": "2023-12-22"
     },
     "iCalUID": "boa5cbh7as7ai4bdu96hu5acs0@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3362954407806000\"",
     "id": "7dec00nik5tgnl1pli9gv4fidc",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=N2RlYzAwbmlrNXRnbmwxcGxpOWd2NGZpZGMgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2023-04-14T13:00:03.000Z",
     "updated": "2023-04-14T13:00:03.903Z",
     "summary": "MRK MERCK & CO., INC. PDUFA",
     "description": "2023-12-16 The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of December 16, 2023. http://www.businesswire.com/news/home/20230413005219/en/FDA-Accepts-Application-for-Merck%E2%80%99s-KEYTRUDA%C2%AE-pembrolizumab-Plus-Chemotherapy-as-First-Line-Treatment-for-Locally-Advanced-Unresectable-or-Metastatic-Gastric-or-Gastroesophageal-Junction-Adenocarcinoma",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2023-12-16"
     },
     "end": {
      "date": "2023-12-16"
     },
     "iCalUID": "7dec00nik5tgnl1pli9gv4fidc@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3363645607758000\"",
     "id": "hi69bvrrk8u4h2vlvtqgqtgs2g",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=aGk2OWJ2cnJrOHU0aDJ2bHZ0cWdxdGdzMmcgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2023-04-18T13:00:03.000Z",
     "updated": "2023-04-18T13:00:03.879Z",
     "summary": "BMY BRISTOL MYERS SQUIBB PDUFA",
     "description": "2023-12-16 U.S. FDA accepted Bristol Myers Squibb and 2seventy bios supplemental Biologics License Application and has assigned a target action date of December 16, 2023 http://www.businesswire.com/news/home/20230413005797/en/Regulatory-Applications-Accepted-Across-Three-Regions-Globally-for-Abecma-for-Earlier-Use-in-Adults-with-Triple-Class-Exposed-Relapsed-andor-Refractory-Multiple-Myeloma",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2023-12-16"
     },
     "end": {
      "date": "2023-12-16"
     },
     "iCalUID": "hi69bvrrk8u4h2vlvtqgqtgs2g@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3363818406922000\"",
     "id": "ot47ttv0gfje9tj8qra90olheo",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=b3Q0N3R0djBnZmplOXRqOHFyYTkwb2xoZW8gNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2023-04-19T13:00:03.000Z",
     "updated": "2023-04-19T13:00:03.461Z",
     "summary": "ARQT Arcutis Biotherapeutics, Inc. PDUFA",
     "description": "2023-12-16 FDA has set a target action date of December 16, 2023 https://www.globenewswire.com/news-release/2023/04/18/2648950/0/en/Arcutis-Announces-FDA-Acceptance-of-New-Drug-Application-for-Roflumilast-Foam-0-3-for-the-Treatment-of-Seborrheic-Dermatitis-in-Individuals-Aged-9-Years-and-Older.html",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2023-12-16"
     },
     "end": {
      "date": "2023-12-16"
     },
     "iCalUID": "ot47ttv0gfje9tj8qra90olheo@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3366410407836000\"",
     "id": "7v4vulpcq6vj524b6ggg70jgsc",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=N3Y0dnVscGNxNnZqNTI0YjZnZ2c3MGpnc2MgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2023-05-04T13:00:03.000Z",
     "updated": "2023-05-04T13:00:03.918Z",
     "summary": "TSVT 2SEVENTY BIO, INC. PDUFA",
     "description": "2023-12-16 The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of December 16, 2023. http://www.businesswire.com/news/home/20230503005950/en/2seventy-bio-Reports-First-Quarter-Financial-Results-and-Recent-Operational-Progress",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2023-12-16"
     },
     "end": {
      "date": "2023-12-16"
     },
     "iCalUID": "7v4vulpcq6vj524b6ggg70jgsc@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3367101607322000\"",
     "id": "frbvf8us5ue368kgcq87oomavc",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=ZnJidmY4dXM1dWUzNjhrZ2NxODdvb21hdmMgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2023-05-08T13:00:03.000Z",
     "updated": "2023-05-08T13:00:03.661Z",
     "summary": "GKOS GLAUKOS CORPORATION PDUFA",
     "description": "2023-12-22 The Prescription Drug User Fee Act (PDUFA) goal date for the completion of the FDAs review of the iDose TR NDA is set for December 22, 2023. http://www.businesswire.com/news/home/20230505005442/en/Glaukos-Announces-FDA-Acceptance-of-NDA-Submission-for-iDose-TR",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2023-12-22"
     },
     "end": {
      "date": "2023-12-22"
     },
     "iCalUID": "frbvf8us5ue368kgcq87oomavc@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3370212008720000\"",
     "id": "ofoc3jgctr0mm988lficaoude0",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=b2ZvYzNqZ2N0cjBtbTk4OGxmaWNhb3VkZTAgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2023-05-26T13:00:04.000Z",
     "updated": "2023-05-26T13:00:04.360Z",
     "summary": "TAK HUTCHMED (China) Limited PDUFA",
     "description": "2023-11-30 If approved, fruquintinib will be the first and only highly selective inhibitor of all three VEGF receptors approved in the U.S. for previously treated metastatic CRC.1,2 The Prescription Drug User Fee Act (PDUFA) goal date assigned by the FDA for this NDA is November 30, 2023. https://www.globenewswire.com/news-release/2023/05/25/2676813/0/en/Takeda-and-HUTCHMED-Announce-New-Drug-Application-NDA-for-Fruquintinib-for-Treatment-of-Previously-Treated-Metastatic-Colorectal-Cancer-Granted-Priority-Review.html",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2023-11-30"
     },
     "end": {
      "date": "2023-11-30"
     },
     "iCalUID": "ofoc3jgctr0mm988lficaoude0@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3371076007374000\"",
     "id": "joavnlu34le67ol79fp6dknof0",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=am9hdm5sdTM0bGU2N29sNzlmcDZka25vZjAgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2023-05-31T13:00:03.000Z",
     "updated": "2023-05-31T13:00:03.687Z",
     "summary": "BMY BRISTOL MYERS SQUIBB PDUFA",
     "description": "2023-11-27 The U.S. Food and Drug Administration assigned a target action date of November 27, 2023 http://www.businesswire.com/news/home/20230528005015/en/U.S.-Food-and-Drug-Administration-Accepts-for-Priority-Review-Bristol-Myers-Squibb%E2%80%99s-Application-for-Repotrectinib-for-the-Treatment-of-Patients-with-Locally-Advanced-or-Metastatic-ROS1-Positive-Non-Small-Cell-Lung-Cancer",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2023-11-27"
     },
     "end": {
      "date": "2023-11-27"
     },
     "iCalUID": "joavnlu34le67ol79fp6dknof0@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3372112820454000\"",
     "id": "ifgsf92m01unnsjgo28ffefes8",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=aWZnc2Y5Mm0wMXVubnNqZ28yOGZmZWZlczggNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2023-06-06T13:00:10.000Z",
     "updated": "2023-06-06T13:00:10.227Z",
     "summary": "SWTX SpringWorks Therapeutics, Inc. PDUFA",
     "description": "2023-11-27 - FDA Extending PDUFA Date by Three Months to Allow More Time to Complete Their Review; New PDUFA Date Set to November 27, 2023 - https://www.sec.gov/Archives/edgar/data/0001773427/000110465923067823/tm2317772d1_ex99-1.htm",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2023-11-27"
     },
     "end": {
      "date": "2023-11-27"
     },
     "iCalUID": "ifgsf92m01unnsjgo28ffefes8@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3372285606938000\"",
     "id": "sqtubgeaim7jat08j1rlv5oe8s",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=c3F0dWJnZWFpbTdqYXQwOGoxcmx2NW9lOHMgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2023-06-07T13:00:03.000Z",
     "updated": "2023-06-07T13:00:03.469Z",
     "summary": "BCLI BRAINSTORM CELL THERAPEUTICS INC. PDUFA",
     "description": "2023-12-08 The Companys BLA for NurOwn has a Prescription Drug User Fee Act action date targeted to occur by December 8, 2023. https://www.sec.gov/Archives/edgar/data/0001137883/000110465923068364/tm2317893d1_8k.htm",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2023-12-08"
     },
     "end": {
      "date": "2023-12-08"
     },
     "iCalUID": "sqtubgeaim7jat08j1rlv5oe8s@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3372631231214000\"",
     "id": "hvfr8jvplmuoefnf3903b48tsk",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=aHZmcjhqdnBsbXVvZWZuZjM5MDNiNDh0c2sgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2023-06-09T13:00:15.000Z",
     "updated": "2023-06-09T13:00:15.607Z",
     "summary": "VRTX VERTEX PHARMACEUTICALS INCORPORATED PDUFA",
     "description": "2023-12-08 - PDUFA target action date of December 8, 2023, for SCD and March 30, 2024, for TDT  http://www.businesswire.com/news/home/20230608005819/en/FDA-Accepts-Biologics-License-Applications-for-exagamglogene-autotemcel-exa-cel-for-Severe-Sickle-Cell-Disease-and-Transfusion-Dependent-Beta-Thalassemia",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2023-12-08"
     },
     "end": {
      "date": "2023-12-08"
     },
     "iCalUID": "hvfr8jvplmuoefnf3903b48tsk@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3373149605456000\"",
     "id": "k14p8eio8mbstr369vdujojfdc",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=azE0cDhlaW84bWJzdHIzNjl2ZHVqb2pmZGMgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2023-06-12T13:00:02.000Z",
     "updated": "2023-06-12T13:00:02.728Z",
     "summary": "CRSP CRISPR Therapeutics AG PDUFA",
     "description": "2023-12-08 The FDA has granted Priority Review for SCD and Standard Review for TDT and assigned Prescription Drug User Fee Act target action dates of December 8, 2023 and March 30, 2024, respectively. https://www.sec.gov/Archives/edgar/data/0001674416/000095017023027129/crsp-20230608.htm",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2023-12-08"
     },
     "end": {
      "date": "2023-12-08"
     },
     "iCalUID": "k14p8eio8mbstr369vdujojfdc@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3374877605812000\"",
     "id": "nvo139120mi9v647forkdoi81c",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=bnZvMTM5MTIwbWk5djY0N2Zvcmtkb2k4MWMgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2023-06-22T13:00:02.000Z",
     "updated": "2023-06-22T13:00:02.906Z",
     "summary": "BLUE BLUEBIRD BIO, INC. PDUFA",
     "description": "2023-12-20 The agency has set a Prescription Drug User Fee Act (PDUFA) goal date of December 20, 2023. http://www.businesswire.com/news/home/20230621695509/en/bluebird-bio-Announces-FDA-Priority-Review-of-the-Biologics-License-Application-for-lovotibeglogene-autotemcel-lovo-cel-for-Patients-with-Sickle-Cell-Disease-SCD-12-years-and-Older-with-a-History-of-Vaso-Occlusive-Events",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2023-12-20"
     },
     "end": {
      "date": "2023-12-20"
     },
     "iCalUID": "nvo139120mi9v647forkdoi81c@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3381962406984000\"",
     "id": "susn8rna0pnk21jiop8n0cq5e0",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=c3VzbjhybmEwcG5rMjFqaW9wOG4wY3E1ZTAgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2023-08-02T13:00:03.000Z",
     "updated": "2023-08-02T13:00:03.492Z",
     "summary": "MRK Merck & Co., Inc. PDUFA",
     "description": "2023-12-27 In chronic cough, Merck received an acceptance from the FDA for the resubmission of the New Drug Application for gefapixant and assigned a target action date of Dec. 27, 2023. https://www.sec.gov/Archives/edgar/data/0000310158/000110465923086030/tm2322190d1_ex99-1.htm",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2023-12-27"
     },
     "end": {
      "date": "2023-12-27"
     },
     "iCalUID": "susn8rna0pnk21jiop8n0cq5e0@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3382308017648000\"",
     "id": "j91329pt3dgimos90hrpu9minc",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=ajkxMzI5cHQzZGdpbW9zOTBocnB1OW1pbmMgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2023-08-04T13:00:08.000Z",
     "updated": "2023-08-04T13:00:08.824Z",
     "summary": "AMGN Amgen PDUFA",
     "description": "2023-12-24 The supplemental New Drug Application (NDA) for full approval of LUMAKRAS for adults with previously treated locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC) was accepted by the FDA for standard review, and a Prescription Drug User Fee Act (PDUFA) target action date of December 24, 2023 has been set. https://www.prnewswire.com/news-releases/amgen-reports-second-quarter-financial-results-301893066.html",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2023-12-24"
     },
     "end": {
      "date": "2023-12-24"
     },
     "iCalUID": "j91329pt3dgimos90hrpu9minc@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3382999206162000\"",
     "id": "l6h2k4rtlf26f1qcn987tg6u00",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=bDZoMms0cnRsZjI2ZjFxY245ODd0ZzZ1MDAgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2023-08-08T13:00:03.000Z",
     "updated": "2023-08-08T13:00:03.081Z",
     "summary": "ZLAB Zai Lab Limited PDUFA",
     "description": "2023-11-27 In May 2023, Zai Lab partner Bristol Myers Squibb (BMS) announced that the NDA for repotrectinib was accepted for priority review by the FDA for the same indication, with a Prescription Drug User Fee Act (PDUFA) date of November 27, 2023. https://www.globenewswire.com/news-release/2023/08/07/2720124/0/en/Zai-Lab-Announces-Second-Quarter-2023-Financial-Results-and-Corporate-Updates.html",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2023-11-27"
     },
     "end": {
      "date": "2023-11-27"
     },
     "iCalUID": "l6h2k4rtlf26f1qcn987tg6u00@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3385245605864000\"",
     "id": "lmjsjpufioqsbnnbvenjifcpc0",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=bG1qc2pwdWZpb3FzYm5uYnZlbmppZmNwYzAgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2023-08-21T13:00:02.000Z",
     "updated": "2023-08-21T13:00:02.932Z",
     "summary": "CALT Calliditas Therapeutics AB PDUFA",
     "description": "2023-12-20 The Prescription Drug User Fee Act (PDUFA) goal date is 20 December 2023. https://www.sec.gov/Archives/edgar/data/0001795579/000110465923093481/tm2324149d1_ex99-1.htm",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2023-12-20"
     },
     "end": {
      "date": "2023-12-20"
     },
     "iCalUID": "lmjsjpufioqsbnnbvenjifcpc0@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3386973605480000\"",
     "id": "cnleftue9n24iau7l8keer9tkg",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=Y25sZWZ0dWU5bjI0aWF1N2w4a2Vlcjl0a2cgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2023-08-31T13:00:02.000Z",
     "updated": "2023-08-31T13:00:02.740Z",
     "summary": "ZEAL Zealand Pharma PDUFA",
     "description": "2023-12-30 US FDA has granted priority review designation to dasiglucagon for the prevention and treatment of hypoglycemia in pediatric patients 7 days of age and older with congenital hyperinsulinism (CHI) for up to 3 weeks of dosing with a Prescription Drug User Fee Act (PDUFA) date on December 30, 2023. https://www.globenewswire.com/news-release/2023/08/30/2734023/0/en/Zealand-Pharma-announces-designation-of-priority-review-by-the-US-FDA-for-dasiglucagon-in-congenital-hyperinsulinism.html",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2023-12-30"
     },
     "end": {
      "date": "2023-12-30"
     },
     "iCalUID": "cnleftue9n24iau7l8keer9tkg@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3392503219046000\"",
     "id": "d82bf1pellu9grll4f8o6u1bk0",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=ZDgyYmYxcGVsbHU5Z3JsbDRmOG82dTFiazAgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2023-10-02T13:00:09.000Z",
     "updated": "2023-10-02T13:00:09.523Z",
     "summary": "HMDCF HUTCHMED PDUFA",
     "description": "2023-11-30 The U.S. Food and Drug Administration (FDA) granted Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) goal date of November 30, 2023. https://www.sec.gov/Archives/edgar/data/0001648257/000164825723000096/hcm-20230929xex99d2.htm",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2023-11-30"
     },
     "end": {
      "date": "2023-11-30"
     },
     "iCalUID": "d82bf1pellu9grll4f8o6u1bk0@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    }
   ]